Business Wire

ADVA

9.12.2021 09:20:09 CET | Business Wire | Press release

Share
ADVA boosts PNT resilience with new software release

ADVA (FSE: ADV) today announced the latest software release of its core and edge timing technology, bringing new levels of PNT security and resilience to synchronization networks. The upgraded series of PTP grandmaster clock solutions now enables operators to automatically harness public key infrastructure. Along with enhanced certificate management, this delivers more robust security and removes complexity. ADVA’s core and mid-sized PTP grandmaster devices now also integrate enhanced aPNT+™ technology , providing advanced jamming and spoofing detection as well as mitigation with automatic switchover in the event of cyberattacks. The software replaces costly hardware devices previously used for PNT protection and achieves enhanced DHS Level 4 Resiliency in PNT self-survivability, the highest in the industry. What’s more, the new software release supports 100Mbit/s over fiber for interconnectivity with optical timing channels from third-part vendors as well as support for PTP profiles for a wide range of industries.

“Today’s timing networks require greater accuracy than ever before. But mission-critical national networks need improved resilience and security as defined by the latest standards. With our trusted PNT assurance solutions, we’re providing the GNSS protection and cybersecurity that today’s operators need to meet current and future challenges,” said Gil Biran, GM of Oscilloquartz, ADVA. “From phase synchronization in critical national infrastructure to traceable timestamping in financial networks, highly precise and protected timing is key to successful operations. This upgrade sets a new standard for secure synchronization and delivers it to more networks than ever before.”

The new 11.1.1 software release features upgrades to ADVA’s comprehensive range of Oscilloquartz edge timing products, the OSA 5412/22 Series, as well as its core synchronization devices, the OSA 5430/40 Series. The solutions now provide multi-layered security for synchronization infrastructure through improved certification management and PKI. As part of ADVA’s intelligent and scalable assured PNT platform, the ADVA aPNT+ , the solutions also feature innovation for detection of spoofing and jamming as well as countermeasures to prevent service disruption. With PTP capabilities for new verticals, including the PTP broadcast profiles (SMPTE ST-2059-2/AES67), the new release will bring precise, reliable synchronization to many new customers.

The new release follows the four layers of augmented protection as defined in the DHS Resilient PNT Conformance Framework (IEEE P1952 Resilient PNT UE working group). These are: antenna level with a new anti-jamming antenna; GNSS receiver level with single and multi-band options; device level with state-of-the-art anti-jamming and spoofing technology; and network level with sophisticated anti-jamming and anti-spoofing technology based on our Ensemble Controller with Sync Director management suite. Additionally, the device and network levels integrate multi-source backup for diversity and multi-level fault-tolerant mitigation for trusted PNT assurance protection, prevention and recovery.

“In a lot of industries and government networks, failure of network synchronization is no longer an option. It could have devastating consequences for a business’s future or even put lives at risk. That’s why more and more customers are deploying our portfolio of the most advanced and comprehensive aPNT+ timing technology. As well as ensuring nanosecond accuracy, our enhanced series of PTP grandmasters now provide the most robust defense against cyberattacks,” commented Nir Laufer, VP of product line management at Oscilloquartz, ADVA. “This release extends many of our most powerful features beyond telecom. It opens the door for government, defense, broadcasters, data centers, smart grids and more to take advantage of technologies like our multi-band receivers and AI-power GNSS protection.”

Further information is available in these slides: https://adva.li/apnt-security-enhancements-slides .

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye